[EN] AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS<br/>[FR] AMINOALCAMIDES POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES, DÉGÉNÉRATIVES OU DÉMYÉLINISANTES DU SYSTÈME NERVEUX CENTRAL
申请人:NENSIUS RES AS
公开号:WO2011000945A9
公开(公告)日:2011-04-07
Substituted Aminoacetamides as Novel Leads for Malaria Treatment
作者:Neil R. Norcross、Caroline Wilson、Beatriz Baragaña、Irene Hallyburton、Maria Osuna‐Cabello、Suzanne Norval、Jennifer Riley、Daniel Fletcher、Robert Sinden、Michael Delves、Andrea Ruecker、Sandra Duffy、Stephan Meister、Yevgeniya Antonova‐Koch、Benigno Crespo、Cristina de Cózar、Laura M. Sanz、Francisco Javier Gamo、Vicky M. Avery、Julie A. Frearson、David W. Gray、Alan H. Fairlamb、Elizabeth A. Winzeler、David Waterson、Simon F. Campbell、Paul A. Willis、Kevin D. Read、Ian H. Gilbert
DOI:10.1002/cmdc.201900329
日期:2019.7.17
Herein we describe the optimization of a phenotypic hit against Plasmodium falciparum based on an aminoacetamide scaffold. This led to N-(3-chloro-4-fluorophenyl)-2-methyl-2-[4-methyl-3-(morpholinosulfonyl)phenyl]amino}propanamide (compound 28) with low-nanomolar activity against the intraerythrocytic stages of the malaria parasite, and which was found to be inactive in a mammalian cell counter-screen